Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 9/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 9/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 9/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18433818 | 1.00 | CHRM2 (0.50) | CHRM2CHRM4CHRM5CHRM3NPC1 | |
| SCHEMBL10313431 | 0.92 | CHRM2 (0.44) | CHRM2CHRM4CHRM5CHRM3NPC1 | |
| SCHEMBL21371335 | 0.81 | CHRM2 (0.46) | CHRM2CHRM4CHRM5CHRM3NPC1 | |
| SCHEMBL933250 | 0.80 | — | — | |
| SCHEMBL12834637 | 0.80 | — | — | |
| SCHEMBL18433436 | 0.79 | CHRM2 (0.44) | CHRM2CHRM4CHRM5CHRM3NPC1 | |
| SCHEMBL18433329 | 0.79 | CHRM2 (0.44) | CHRM2CHRM4CHRM5CHRM3NPC1 | |
| SCHEMBL21805102 | 0.79 | — | — | |
| SCHEMBL4285047 | 0.79 | — | — | |
| SCHEMBL15810295 | 0.78 | CHRM2 (0.47) | CHRM2CHRM4CHRM5CHRM3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015134366-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-11 | — | — | WO | disclosed |
| US-20090131412-A1 | NOVEL 2-QUINOLONE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131412-A1 | NOVEL 2-QUINOLONE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131412-A1 | NOVEL 2-QUINOLONE DERIVATIVE | SCN1B, OPRL1, SCN1A | CHRM2 338/4885CHRM4 905/4885CHRM5 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.